Remember: “One size fits nothing in ADMET/PK”
when to use recombinant versus microsomal CYP inhibition?
when should you use a cassette versus discrete PK approach?
what exactly is PK/PD in your project?
can you use the rat alone to predict human PK?
No matter if your project is in early drug discovery, lead optimization or already in candidate profiling during pre-clinical development, CapEval Pharma can help to find the right assay conditions to improve, fine-tune and/or fully characterize drug-likeness, ADME, DDI potential and cross-species PK including human PK and dose prediction.
We can help you with:
Evaluation of in silico data and physicochemical properties
Proposal for early high throughput ADME assays
Detailed SOPs and technical help for all advanced ADME assays
Metabolite identification incl. CYP or other enzyme mapping
Transporter evaluation (substrate and inhibition format)
Advice how to approach new 2012 FDA guidance for DDI
Metabolites in safety testing (MIST FDA Guidance)
Toxicophores and reactive intermediate assays
New early safety assays (e.g. HCS screening, Greenscreen)
CYP induction studies
Design and conduct of PK experiments (in house or CRO) for rodents, rabbit, dog, minipig, NHP
Target-specific PK/PD approaches
Allometry, human PK and dose prediction
Radiolabeled in vitro met ID in combination with rodent/non-rodent mass balance/metabolite profiling, QWBA